

# Vincent van Pesch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8562953/publications.pdf>

Version: 2024-02-01

142  
papers

6,320  
citations

76326

40  
h-index

76900

74  
g-index

152  
all docs

152  
docs citations

152  
times ranked

7209  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bingâ€œNeel syndrome hidden by multiple sclerosis, a challenging overlay of diseases. <i>Acta Neurologica Belgica</i> , 2022, 122, 227-229.	1.1	0
2	Clinical usefulness of the CSF $\text{A}\beta_{1-42}/\text{A}\beta_{1-40}$ ratio for Alzheimerâ€™s disease diagnosis: a retrospective study in a Belgian academic hospital. <i>Acta Neurologica Belgica</i> , 2022, 122, 245-247.	1.1	1
3	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. <i>Multiple Sclerosis Journal</i> , 2022, , 135245852210845.	3.0	2
4	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. <i>Pharmacoeconomics</i> , 2022, 40, 323-339.	3.3	3
5	Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.1	12
6	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. <i>European Journal of Neurology</i> , 2022, , .	3.3	1
7	O36â€œ... Ocrelizumab real-world effectiveness in patients with relapsing and primary progressive multiple sclerosis: MuSicalE baseline data. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A24.3-A25.	1.9	0
8	Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0263595.	2.5	22
9	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 755-766.	3.0	11
10	The central vein sign in multiple sclerosis patients with vascular comorbidities. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1057-1065.	3.0	16
11	Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. <i>Journal of Neurology</i> , 2021, 268, 751-757.	3.6	154
12	Paraneoplastic encephalomyelitis revealing burned-out seminoma. <i>Acta Neurologica Belgica</i> , 2021, 121, 767-769.	1.1	4
13	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.	3.0	3
14	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021, 96, .	1.1	41
15	Simultaneous bilateral optic neuropathy and myelitis revealing paraneoplastic neurological syndrome associated with multiple onconeural antibodies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102789.	2.0	2
16	Needs and Experiences of Children and Adolescents with Pediatric Multiple Sclerosis and Their Caregivers: A Systematic Review. <i>Children</i> , 2021, 8, 445.	1.5	7
17	Cutaneous diseases related to a hyperactive T-cell response in ocrelizumab-treated multiple sclerosis patients. <i>Journal of Neurology</i> , 2021, 268, 4376-4378.	3.6	3
18	Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e543-e553.	1.1	54

#	ARTICLE	IF	CITATIONS
19	Effects of prolonged-release fampridine on multiple sclerosis-related gait impairments. A crossover, double-blinded, placebo-controlled study. <i>Clinical Biomechanics</i> , 2021, 86, 105382.	1.2	2
20	Extracellular vesicles for the treatment of central nervous system diseases. <i>Advanced Drug Delivery Reviews</i> , 2021, 174, 535-552.	13.7	39
21	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 208, 106180.	4.7	21
22	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. <i>Journal of the Neurological Sciences</i> , 2021, 430, 118067.	0.6	9
23	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021, 96, e783-e797.	1.1	54
24	Mechanism of Cellular Formation and In Vivo Seeding Effects of Hexameric $\text{A}\beta_{1-42}$ Amyloid Assemblies. <i>Molecular Neurobiology</i> , 2021, 58, 6647-6669.	4.0	8
25	Comment on "Paraneoplastic encephalomyelitis revealing burned-out seminoma": confirmed case of anti-Kelch-like protein-11 encephalomyelitis. <i>Acta Neurologica Belgica</i> , 2021, , 1.	1.1	3
26	Molecular Mechanisms of Immunosenescence and Inflammaging: Relevance to the Immunopathogenesis and Treatment of Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 811518.	2.4	16
27	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 912-923.	3.0	52
28	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 79-90.	3.0	52
29	Anti-Ma2/Ta paraneoplastic rhombencephalitis in a patient with lung cancer responsive to anti-PD1 therapy. <i>Acta Neurologica Belgica</i> , 2020, 120, 451-452.	1.1	3
30	Treatment response score to glatiramer acetate or interferon beta-1a. <i>Neurology</i> , 2020, 96, 10.1212/WNL.0000000000010991.	1.1	6
31	Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study. <i>Annals of Neurology</i> , 2020, 88, 1034-1042.	5.3	89
32	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 1398.	9.0	21
33	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	7.6	24
34	Improvement in progressive multifocal leukoencephalopathy after pembrolizumab-induced immune reconstruction inflammatory syndrome in a patient with follicular lymphoma. <i>EJHaem</i> , 2020, 1, 585-588.	1.0	2
35	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020, 143, 1400-1413.	7.6	32
36	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1031-1044.	3.0	39

#	ARTICLE	IF	CITATIONS
37	CSF microRNAs discriminate MS activity and share similarity to other neuroinflammatory disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	23
38	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 307-316.	10.2	219
39	Acute Susac Syndrome in a Recent User of Adulterated Cocaine: Levamisole as a Triggering Factor?. <i>Case Reports in Neurology</i> , 2020, 12, 78-83.	0.7	4
40	Intravenous immunoglobulin-induced aseptic meningitis in a patient with Miller Fisher syndrome. <i>Acta Neurologica Belgica</i> , 2020, 120, 1015-1016.	1.1	1
41	Telecommunication and rehabilitation for patients with multiple sclerosis: access and willingness to use. A cross-sectional study. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2020, 56, 403-411.	2.2	11
42	Effects of Fampridine in People with Multiple Sclerosis: A Systematic Review and Meta-analysis. <i>CNS Drugs</i> , 2019, 33, 1087-1099.	5.9	19
43	MOG antibody-related isolated rhombencephalitis revealed by paroxysmal dysarthria. <i>Journal of the Neurological Sciences</i> , 2019, 405, 116417.	0.6	4
44	Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid A $\beta$ 242 and T-Tau assays for Alzheimer's disease diagnosis. <i>Journal of Neurology</i> , 2019, 266, 2304-2311.	3.6	34
45	Premotor dorsal white matter integrity for the prediction of upper limb motor impairment after stroke. <i>Scientific Reports</i> , 2019, 9, 19712.	3.3	11
46	Which treatment strategies for polyrefractory Neuro-Behçet disease?. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 203-205.	2.0	5
47	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 458-468.	1.9	71
48	Response to correspondence: "Interferon alpha might be an alternative therapeutic choice for refractory neuro-Behçet's disease" Authors reply. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, 154.	2.0	1
49	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 235-243.	2.0	35
50	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 175.	7.4	336
51	International consensus on quality standards for brain health-focused care in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1809-1818.	3.0	55
52	Timed Up-and-Go and 2-Minute Walk Test in patients with multiple sclerosis with mild disability: reliability, responsiveness and link with perceived fatigue. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2019, 55, 450-455.	2.2	29
53	Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. <i>European Journal of Neurology</i> , 2019, 26, 363-370.	3.3	12
54	Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis. <i>Patient Related Outcome Measures</i> , 2018, Volume 9, 1-10.	1.2	27

#	ARTICLE	IF	CITATIONS
55	Herpes simplex encephalitis relapse associated with positive N-methyl-d-aspartate receptor antibodies. <i>Acta Neurologica Belgica</i> , 2018, 118, 533-535.	1.1	3
56	Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus. <i>Acta Neurologica Belgica</i> , 2018, 118, 7-11.	1.1	10
57	Auto-immune hepatitis in a patient with multiple sclerosis treated with alemtuzumab. <i>Acta Neurologica Belgica</i> , 2018, 118, 331-333.	1.1	12
58	A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis. <i>Acta Neurologica Belgica</i> , 2018, 118, 161-168.	1.1	6
59	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 642-652.	3.0	37
60	Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1569-1577.	3.0	8
61	Prophylactic treatment against GM-CSF, but not IL-17, abolishes relapses in a chronic murine model of multiple sclerosis. <i>European Journal of Immunology</i> , 2018, 48, 1883-1891.	2.9	12
62	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 11-19.	2.0	17
63	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 1407.	9.0	20
64	A Role for GDNF and Soluble APP as Biomarkers of Amyotrophic Lateral Sclerosis Pathophysiology. <i>Frontiers in Neurology</i> , 2018, 9, 384.	2.4	33
65	Are simplified indices of exercise tolerance well correlated to VO <sub>2</sub> peak among patients with multiple sclerosis: A case-control study. <i>Annals of Physical and Rehabilitation Medicine</i> , 2018, 61, e45.	2.3	0
66	Free Kappa light chains in neuroinflammatory disorders: Complement rather than substitute?. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 352-358.	2.1	13
67	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 266-276.	3.0	30
68	Early disturbances in multimodal evoked potentials as a prognostic factor for long-term disability in relapsing-remitting multiple sclerosis patients. <i>Clinical Neurophysiology</i> , 2017, 128, 561-569.	1.5	27
69	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 196-203.	1.9	49
70	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 271-281.	10.2	134
71	Corticosteroids in the management of acute multiple sclerosis exacerbations. <i>Acta Neurologica Belgica</i> , 2017, 117, 623-633.	1.1	31
72	Decrease of blood anti- $\alpha$ 1,3 Galactose Abs levels in multiple sclerosis (MS) and clinically isolated syndrome (CIS) patients. <i>Clinical Immunology</i> , 2017, 180, 128-135.	3.2	25

#	ARTICLE	IF	CITATIONS
73	Cramp&fasciculation syndrome associated with monofocal motor neuropathy. <i>Muscle and Nerve</i> , 2017, 56, 828-832.	2.2	1
74	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. <i>Neurology</i> , 2017, 89, 1050-1059.	1.1	38
75	Fatigue and physical fitness of mildly disabled persons with multiple sclerosis: a cross-sectional study. <i>International Journal of Rehabilitation Research</i> , 2017, 40, 268-274.	1.3	17
76	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1346-1357.	3.0	18
77	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017, 140, 2426-2443.	7.6	94
78	IL-22, GM-CSF and IL-17 in peripheral CD4+ T cell subpopulations during multiple sclerosis relapses and remission. Impact of corticosteroid therapy. <i>PLoS ONE</i> , 2017, 12, e0173780.	2.5	33
79	Reversible Akinetic Mutism after Aneurysmal Subarachnoid Haemorrhage in the Territory of the Anterior Cerebral Artery without Permanent Ischaemic Damage to Anterior Cingulate Gyri. <i>Case Reports in Neurological Medicine</i> , 2016, 2016, 1-6.	0.4	5
80	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405.	7.6	281
81	Anti&scsp>SPAG</scsp>16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index. <i>European Journal of Neurology</i> , 2016, 23, 722-728.	3.3	11
82	New-Onset Refractory Status Epilepticus: More Investigations, More Questions. <i>Case Reports in Neurology</i> , 2016, 8, 127-133.	0.7	9
83	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1343-1349.	1.9	63
84	Voxel-based lesion-symptom mapping of stroke lesions underlying somatosensory deficits. <i>NeuroImage: Clinical</i> , 2016, 10, 257-266.	2.7	88
85	Effectiveness and safety of natalizumab in real-world clinical practice: Review of observational studies. <i>Clinical Neurology and Neurosurgery</i> , 2016, 149, 55-63.	1.4	19
86	Predictors of long&term disability accrual in relapse&onset multiple sclerosis. <i>Annals of Neurology</i> , 2016, 80, 89-100.	5.3	158
87	Label&free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis. <i>Proteomics</i> , 2016, 16, 1154-1165.	2.2	26
88	Early relapse with tumefactive MS lesion upon initiation of fingolimod therapy. <i>Acta Neurologica Belgica</i> , 2016, 116, 95-97.	1.1	9
89	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 520-532.	3.0	34
90	A basic overview of multiple sclerosis immunopathology. <i>European Journal of Neurology</i> , 2015, 22, 3-13.	3.3	158

#	ARTICLE	IF	CITATIONS
91	Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. <i>Proteomics</i> , 2015, 15, 3361-3369.	2.2	32
92	Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2015, 1, 205521731560019.	1.0	5
93	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. <i>Brain</i> , 2015, 138, 632-643.	7.6	54
94	Idiopathic limbic encephalitis associated with antibodies to glutamic acid decarboxylase. <i>Acta Neurologica Belgica</i> , 2015, 115, 165-167.	1.1	1
95	Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 479-491.	3.7	43
96	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 405.	9.0	100
97	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015, 138, 3287-3298.	7.6	162
98	Regulation of Treg-associated CD39 in multiple sclerosis and effects of corticotherapy during relapse. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1533-1545.	3.0	21
99	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1159-1171.	3.0	36
100	Susac-Like Syndrome in a Chronic Cocaine Abuser: Could Levamisole Play a Role?. <i>Journal of Medical Toxicology</i> , 2015, 11, 124-128.	1.5	25
101	Ventricular arrhythmia in a male MS patient on fingolimod. <i>Acta Neurologica Belgica</i> , 2015, 115, 77-79.	1.1	7
102	Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. <i>PLoS ONE</i> , 2015, 10, e0122686.	2.5	122
103	Fingolimod Increases CD39-Expressing Regulatory T Cells in Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2014, 9, e113025.	2.5	45
104	Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose. <i>Case Reports in Neurological Medicine</i> , 2014, 2014, 1-4.	0.4	3
105	Risk of relapse phenotype recurrence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1511-1522.	3.0	73
106	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 739-746.	3.0	148
107	Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. <i>Annals of Neurology</i> , 2014, 76, 880-890.	5.3	67
108	Brainstem somatosensory and auditory evoked responses in central pontine myelinolysis. <i>Acta Neurologica Belgica</i> , 2014, 114, 225-226.	1.1	0

#	ARTICLE	IF	CITATIONS
109	Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program. <i>Acta Neurologica Belgica</i> , 2014, 114, 167-178.	1.1	21
110	Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter study. <i>Journal of Neurology</i> , 2013, 260, 1258-1262.	3.6	9
111	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. <i>Brain</i> , 2013, 136, 3609-3617.	7.6	140
112	Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. <i>Journal of Proteomics</i> , 2013, 78, 312-325.	2.4	58
113	Concomitant Analysis of Arterial, Venous, and CSF Flows using Phase-Contrast MRI: A Quantitative Comparison Between MS Patients and Healthy Controls. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 1314-1321.	4.3	51
114	Fluctuations of MS births and UV-light exposure. <i>Acta Neurologica Scandinavica</i> , 2013, 127, 301-308.	2.1	10
115	Anti-N-Methyl-D-Aspartate Receptor Encephalitis with Favorable Outcome Despite Prolonged Status Epilepticus. <i>Neurocritical Care</i> , 2013, 18, 89-92.	2.4	23
116	Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e63480.	2.5	26
117	Partly reversible central auditory dysfunction induced by cerebral vasospasm after subarachnoid hemorrhage. <i>Journal of Neurosurgery</i> , 2013, 119, 1125-1128.	1.6	12
118	Transient perioperative visual loss after an elective neurosurgical procedure. <i>Acta Anaesthesiologica Belgica</i> , 2013, 64, 109-113.	0.1	2
119	EXPOSURE TO INTERFERON- $\beta$ THERAPY IN EARLY PREGNANCY: A LITERATURE REVIEW OF PREGNANCY OUTCOMES IN WOMEN WITH MULTIPLE SCLEROSIS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, A17.2-A17.	1.9	2
120	The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. <i>Multiple Sclerosis Journal</i> , 2012, 18, 974-982.	3.0	56
121	The Kurtzke EDSS rank stability increases 4â€¦years after the onset of multiple sclerosis: results from the MSBase Registry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 305-310.	1.9	37
122	Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome. <i>Journal of Neurochemistry</i> , 2012, 123, 568-577.	3.9	11
123	Increasing age at disability milestones among MS patients in the MSBase Registry. <i>Journal of the Neurological Sciences</i> , 2012, 318, 94-99.	0.6	35
124	Vitamin D supplementation in multiple sclerosis patients in 2012: hype or reality as an adjunctive therapy?. <i>Acta Neurologica Belgica</i> , 2012, 112, 325-325.	1.1	0
125	Upregulation of IL-17, but not of IL-9, in circulating cells of CIS and relapsing MS patients. Impact of corticosteroid therapy on the cytokine network. <i>Journal of Neuroimmunology</i> , 2012, 243, 73-80.	2.3	26
126	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. <i>PLoS ONE</i> , 2012, 7, e38661.	2.5	35



#	ARTICLE	IF	CITATIONS
127	Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. PLoS ONE, 2012, 7, e48078.	2.5	166
128	Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Multiple Sclerosis International, 2011, 2011, 1-9.	0.8	52
129	Encéphalopathie à complexes triphasiques et syndrome de Guillain-Barré retardé lors d'une intoxication aiguë par un herbicide « chlorophénoxy ». Annales Francaises De Medecine D'Urgence, 2011, 1, 349-351.	0.1	0
130	Recurrent Miller Fisher Syndrome with Vestibular Involvement. European Neurology, 2011, 66, 210-214.	1.4	5
131	Neurofilament ELISA validation. Journal of Immunological Methods, 2010, 352, 23-31.	1.4	86
132	Short commentary on "a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking". Multiple Sclerosis Journal, 2010, 16, 129-132.	3.0	7
133	Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. Laboratoriums Medizin, 2010, 34, 1-12.	0.6	3
134	A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology, 2009, 73, 1914-1922.	1.1	653
135	Polymerase chain reaction analysis and oligoclonal antibody in the cerebrospinal fluid from 34 patients with varicella-zoster virus infection of the nervous system. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 938-942.	1.9	71
136	Clinical, electrophysiological and brain imaging features during recurrent ictal cortical blindness associated with chronic liver failure. Acta Neurologica Belgica, 2006, 106, 215-8.	1.1	9
137	Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. Journal of Neurology, 2005, 252, 1217-1222.	3.6	51
138	The Leader Protein of Theiler's Virus Interferes with Nucleocytoplasmic Trafficking of Cellular Proteins. Journal of Virology, 2004, 78, 4357-4362.	3.4	106
139	Characterization of the Murine Alpha Interferon Gene Family. Journal of Virology, 2004, 78, 8219-8228.	3.4	187
140	Characterization of Interferon- $\beta$ 13, a Novel Constitutive Murine Interferon- $\beta$ Subtype. Journal of Biological Chemistry, 2003, 278, 46321-46328.	3.4	41
141	The Leader Protein of Theiler's Virus Inhibits Immediate-Early Alpha/Beta Interferon Production. Journal of Virology, 2001, 75, 7811-7817.	3.4	117
142	Clinical Significance of Antiproteinase 3 Antibody Positivity in cANCA-Positive Patients. Clinical Rheumatology, 1999, 18, 279-282.	2.2	9